Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2

Status

Terminated 5Completed 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 2Tumor-Agnostic 1Thoracic 1Myeloid 1Lymphoid 1Gastrointestinal 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × tozasertib × Clear all
NCT02532868 2015-08-26

A VX-680 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Cancer (0457-002)

Merck Sharp & Dohme LLC

Phase 1 Terminated
27 enrolled
Tumor-Agnostic

Neoplasms

NCT00290550 2015-07-27

A Phase IIA Study of MK0457 in Patients With Cancer of the Lung (0457-006)

Merck Sharp & Dohme LLC

Phase 2 Terminated
22 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00099346 2015-06-17

MK0457 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Colorectal Cancer and Other Advanced Solid Tumors (0457-001)

Merck Sharp & Dohme LLC

Phase 1 Terminated
Gastrointestinal

Colorectal Neoplasms

NCT00500006 2015-01-30

A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)

Merck Sharp & Dohme LLC

Phase 1 Terminated
3 enrolled
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00405054 2015-01-26

A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008)

Merck Sharp & Dohme LLC

Phase 2 Terminated
52 enrolled
Other hematologic neoplasm

Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡